FDA cited Pharmaplast S.A.E. for failing to test drug components, including glycerin and ethanol, for dangerous contaminants.
What happened
FDA inspected Pharmaplast S.A.E.'s Alexandria drug manufacturing facility from November 6 to November 10, 2022. It found the firm did not test each component lot for identity and did not test ethanol for methanol or ensure glycerin was tested for diethylene glycol (DEG) or ethylene glycol (EG). It also found cleaning validation did not include transfer carriage vessels used to move drug and device components, creating a cross-contamination risk.
What FDA found
The firm failed to test each incoming component lot for identity and conformity with specifications and failed to validate supplier test results.
21 CFR 211.84(d)(1) and (2)The firm did not test ethanol for methanol or ensure glycerin was tested for diethylene glycol (DEG) or ethylene glycol (EG).
21 CFR 211.84(d)(1) and (2)The firm's cleaning and maintenance procedures did not cover all product-contact equipment, including transfer carriage vessels.
21 CFR 211.67(b)
What FDA wants
FDA asks the firm to correct the violations promptly and respond in writing within 15 working days, including plans and results for component testing, DEG/EG and methanol testing, cleaning validation, and risk assessments for affected U.S. products.
Who should pay attention
- companies that rely on this contract manufacturer for finished drugs
- drugmakers using glycerin or ethanol in products
- quality teams responsible for supplier verification and incoming testing
This is a summary. Read the original letter on fda.gov.